Positron Emission Tomography in the Diagnosis and Monitoring of Patients with Nonseminomatous Germ Cell Tumours
Authors:
T. Büchler 1; K. Šimonová 2; P. Fencl 2; J. Abrahámová 1
Authors‘ workplace:
Onkologické oddělení, Fakultní Thomayerova nemocnice a 1. LF UK, Praha
1; Oddělení nukleární medicíny a PET centrum, Nemocnice Na Homolce, Praha
2
Published in:
Klin Onkol 2011; 24(6): 413-417
Category:
Reviews
Overview
The role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the diagnosis and monitoring of nonseminomatous germ cell tumours is currently unclear. Clinical studies have suggested that FDG-PET has relatively low sensitivity and specificity in the setting of initial staging and viability assessment of post-chemotherapy residual lesions. On the other hand, FDG-PET provides potentially useful information in patients with elevated tumour markers and/or multiple residual lesions with limited resectability. Other possible indications of FDG-PET are the early assessment of tumour chemosensitivity and the diagnosis of inflammatory treatment complications.
Key words:
positron emission tomography – germ cell tumour – diagnosis – therapy
With the support of the Czech Ministry of Health’s grant IGA NS 10420-3/2009.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Submitted:
2. 6. 2011
Accepted:
18. 8. 2011
Sources
1. Dušek L, Mužík J, Gelnarová E et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2010; 23(5): 311–324.
2. Abrahámová J, Dušek L, Mužík J. Epidemiologie nádorů varlat. In: Vybrané otázky onkologie XIII. 17. onkologicko-urologické sympozium a 13. mammologické sympozium, Praha 26.–28. 11. 2009: 12–14.
3. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15(2): 594–593.
4. Albers P, Bender H, Yilmaz H et al. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 1999; 53(4): 808–811.
5. Hain SF, O’Doherty MJ, Timothy AR et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27(5): 590–594.
6. Lassen U, Daugaard G, Eigtved A et al. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003; 30(3): 396–402.
7. Huddart RA, O’Doherty MJ, Padhani A et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007; 25(21): 3090–3095.
8. de Wit M, Brenner W, Hartmann M et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 2008; 19(9): 1619–1623.
9. Albers P, Siener R, Kliesch S et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003; 21(8): 1505–1512.
10. De Santis M, Becherer A, Bokemeyer C et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22(6): 1034–1039.
11. Becherer A, De Santis M, Karanikas G et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 2005; 54(2): 284–288.
12. Schmoll HJ, Jordan K, Huddart R et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v140–v146.
13. Oechsle K, Hartmann M, Brenner W et al. [18F]Fluoroeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 2008; 26(36): 5930–5935.
14. Fosså SD, Qvist H, Stenwig AE et al. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992; 10(4): 569–573.
15. Kollmannsberger C, Oechsle K, Dohmen BM et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 2002; 94(9): 2353–2362.
16. Karapetis CS, Strickland AH, Yip D et al. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. Intern Med J 2003; 33(9–10): 427–435.
17. Hain SF, O’Doherty MJ, Timothy AR et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000; 83(7): 863–869.
18. Sanchez D, Zudaire JJ, Fernandez JM et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int 2002; 89(9): 912–916.
19. Aide N, Poulain L, Briand M et al. Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging 2009; 36(3): 396–405.
20. Beyer J, Kingreen D, Krause M et al. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 1997; 79(1): 161–168.
21. Pfannenberg AC, Oechsle K, Kollmannsberger C et al. Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker. Rofo 2004; 176(1): 76–84.
22. Büchler T, Foldyna M, Nepomucká J et al. Extragonadal germ cell tumours - results from a single centre. EJC Supplements 2009; 7: 447.
23. Büchler T, Kubánková P, Boublíkova L et al. Detection of second malignancies during long-term follow-up of testicular cancer survivors. Cancer 2011; 117(18): 4212–4218.
24. Wong PS, Lau WE, Worth LJ et al. Clinically important detection of infection as an ‘incidental’ finding during cancer staging using FDG-PET/CT. Intern Med J 2011. Epub ahead of print.
25. Mahfouz T, Miceli MH, Saghafifar F et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol 2005; 23(31): 7857–7863.
26. Sonet A, Graux C, Nollevaux MC et al. Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol 2007; 86(1): 9–15.
27. Hain SF, Beggs AD. Bleomycin-induced alveolitis detected by FDG positron emission tomography. Clin Nucl Med 2002; 27(7): 522–523.
28. Kirsch J, Arrossi AV, Yoon JK et al. FDG positron emission tomography/computerized tomography features of bleomycin-induced pneumonitis. J Thorac Imaging 2006; 21(3): 228–230.
29. von Rohr L, Klaeser B, Joerger M et al. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie 2007; 30(6): 320–323.
30. Büchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin’s disease--a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica 2007; 92(11): e120–e121.
31. Bosl GJ, Motzer RJ. Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy. J Clin Oncol 2010; 28(4): 519–521.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2011 Issue 6
Most read in this issue
- Castleman Disease
- Trabectedin Registry
- Predictive Values of the Ultrasound Parameters, CA-125 and Risk of Malignancy Index in Patients with Ovarian Cancer
- The Role of Chemotherapy and Targeted antiVEGF- and antiEGFR-Therapy in Metastatic Colorectal Cancer: a Case Report of Long-Term and Intensive Response